---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310595"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:58:43.147109+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass

## Summary
- Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.
- Serum Activin E suppressed up to 78%; durable reductions support once or twice-yearly dosing.
- No severe TEAEs, no discontinuations, no clinically meaningful changes in lipids or liver function.
- Phase 2 planning for monotherapy, add-on to incretins, and maintenance post-incretin therapy.
- Next data: Q1 2026 6-month follow-up from 240 mg cohort and 3-month from 400 mg cohort.

## SEC filing metadata
- accession: 0001193125-25-310595
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/0001193125-25-310595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/d20484d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310595
- JSON: https://secwatch.observer/filing/0001193125-25-310595.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.